US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

209.18

-18.5750-8.16%

Volume:379.30K

Turnover:81.31M

Market Cap:528.06M

PE:- -

High:223.71

Open:220.01

Low:208.99

Close:227.75

52wk High:341.93

52wk Low:102.35

Shares:2.52M

Float Shares:2.52M

Volume Ratio:2.16

T/O Rate:15.02%

Dividend:0.91

Dividend Rate:0.44%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

New Abdominoplasty Trial Signals Steady Demand in Procedure-Driven Healthcare

Community Healthcare management to meet virtually with Truist

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Stryker (SYK)

Ultragenyx Monetizes FDA Priority Review Voucher Asset

Clearmind Medicine submits psychedelic therapy recommendations to FDA

Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Wednesday

MT Newswires Live

Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA

AbbVie’s telisotuzumab adizutecan gets two FDA Breakthrough Therapy Designations

Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

J.P. Morgan Remains a Buy on Gilead Sciences (GILD)

Arrowhead announces US FDA granted plozasiran entry into STAR program

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analysts’ Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)

Otsuka Subsidiary Initiates US FDA Submission for Kidney Disease Drug

MT Newswires Live

Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/LABU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":209.175,"timestamp":1791473956344,"preClose":227.75,"halted":0,"volume":379301,"delay":0,"changeRate":-0.08155872667398459,"floatShares":2524486,"shares":2524486,"eps":0,"marketStatus":"Trading","change":-18.575,"latestTime":"10-08 11:39:16 EDT","open":220.01,"high":223.7074,"low":208.985,"amount":81305122.75015001,"amplitude":0.064643,"askPrice":209.73,"askSize":30,"bidPrice":209,"bidSize":12,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791489600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":227.75,"sharesOutstanding":3074486,"nav":230.529,"aum":581967299.18,"dividendRate":0.004355,"bidAskSpread":0.002401,"preHourTrading":{"tag":"盘前","latestPrice":220.18,"preClose":227.75,"latestTime":"09:29 EDT","volume":6169,"amount":1385605.45651,"timestamp":1791466199999,"change":-7.57,"changeRate":-0.033238,"amplitude":0.038727},"postHourTrading":{"tag":"盘后","latestPrice":228.7,"preClose":227.75,"latestTime":"19:59 EDT","volume":2729,"amount":623483.6155,"timestamp":1791417573520,"change":0.95,"changeRate":0.004171,"amplitude":0.004911},"volumeRatio":2.157401,"impliedVol":0.9575,"impliedVolPercentile":0.6693},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2524486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.157401,"shares":2524486,"dividePrice":0.911,"high":223.7074,"amplitude":0.064643,"preClose":227.75,"low":208.985,"week52Low":102.3547,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":209.175,"committee":-0.428571,"eps":0,"divideRate":0.004355,"volume":379301,"delay":0,"ttmEps":0,"open":220.01,"prevYearClose":159.39,"prevWeekClose":248.72,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":249.65,"twentyDayClose":266,"sixtyDayClose":277.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673014180","title":"VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2673014180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673014180?lang=en_us&edition=fundamental","pubTime":"2026-10-08 01:00","pubTimestamp":1791392422,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, October 7th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA), a developer of next-generation antibody-based cancer the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-fda-aligned-methods-to-reduce-animal-testing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-fda-aligned-methods-to-reduce-animal-testing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NDX","BK4139","JEPQ","BK4588","XBI","NVIW.SI","NQmain","TQQQ","LABU","BK4581","QYLG","QQQ","QID","GPIQ","TQQY","QQQM",".IXIC","BK4585","MNQmain","FTEC","PSQ","QQQA","QDTE","QQQE","03086","TECS","QQQJ","QLD","VRXA","SQQQ","QQQY","IYW","ONEQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011717","title":"New Abdominoplasty Trial Signals Steady Demand in Procedure-Driven Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011717","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011717?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:30","pubTimestamp":1791390623,"startTime":"0","endTime":"0","summary":"Lam Research Corp ($LRCX) announced an update on their ongoing clinical study. The study, formally titled “Prospective One-Year Evaluation of the S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/new-abdominoplasty-trial-signals-steady-demand-in-procedure-driven-healthcare?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/new-abdominoplasty-trial-signals-steady-demand-in-procedure-driven-healthcare?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0210536198.USD","KNOW","QQQG","LU1066053197.SGD","LRCX","HCSG","LU0942090050.USD","LU0061474960.USD","LU2244417387.USD","IETC","XLV","BK4137","IE00BJJMRY28.SGD","LU0868494708.USD","LU2931357623.SGD","XBI","LU1992135399.USD","EPAI","BOBP","LU1974910355.USD","RDVY","COWG","LU0320765059.SGD","LU2089985449.USD","LU0157215616.USD","CLSE","LU0187121727.USD","RDVI","LU1244550221.USD","TINY","BAI","LRCU","LU0672654240.SGD","IE00B1XK9C88.USD","LU1066051811.HKD","LU1496350502.SGD","LU1674673691.USD","PSI","BK4588","LABU","TEK","IE00BQXX3C00.GBP","LRCC","RULE","LU1548497426.USD","TDV","ABFL","BK4543","BK4581","LU2357305700.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673117740","title":"Community Healthcare management to meet virtually with Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2673117740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673117740?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:30","pubTimestamp":1791390612,"startTime":"0","endTime":"0","summary":"Analyst Lewis holds a virtual meeting with management on October 7 hosted by Truist. Published first on TheFly – the ultimate source for real-time,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/community-healthcare-management-to-meet-virtually-with-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/community-healthcare-management-to-meet-virtually-with-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","XBI","BK4585","BK4581","CHCT","BK4225","KBWY","XLV","BK4203"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011517","title":"Novartis announces FDA approval of Rhapsido for symptomatic dermographism","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011517","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011517?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:50","pubTimestamp":1791388212,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that the Food and Drug Administration approved Rhapsido as the first treatment for adults with symptomatic dermographism i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","BK4532","LFSC","IE0009355771.USD","NVS","PINK","IEIH","MEDI","GDOC","BBP","LU0208291251.USD","LU0211331839.USD","IE00B4R5TH58.HKD","RSPH","TBXU","IE00BJJMRZ35.SGD","IE0002141913.USD","IDNA","NVIB","XLVX","GNMX","IE00B2B36J28.USD","MEDX","BMED","SYNB","PPH","LABU","TECB","IE00BJT1NW94.SGD","BK4585","BK4007","IYH","IBB","MRNY","IE00BFTCPJ56.SGD","MRNX","LU0320765489.SGD","LU0070302665.USD","PSCH","BK4588","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673118620","title":"Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673118620","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673118620?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:45","pubTimestamp":1791387900,"startTime":"0","endTime":"0","summary":"In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible ur","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376686/0/en/novartis-rhapsido-remibrutinib-receives-fda-approval-as-first-treatment-for-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","LU1989772840.SGD","MEDI","XLVX","LABU","LU0267386448.USD","TECB","KBWB","LU0390134368.USD","RSPH","PSCH","BBP","LU1720051017.SGD","LFSC","IE00BZ1G4Q59.USD","LU1064131342.USD","SYNB","LU1668664300.SGD","LU1244550221.USD","IEIH","LU2487616109.SGD","LU2264538146.SGD","MRNY","IYH","GNMX","BK4581","IE00B3S45H60.SGD","LU1720051108.HKD","NVIB","IDNA","LU2357305700.SGD","LU2023251221.USD","BMED","LU1791710582.SGD","PINK","LU0912757837.SGD","LU0528227936.USD","GDOC","MRNX","SD","LU0106831901.USD","TBXU","LU2089284900.SGD","BK4585","IAI","BK4504","LU2028103732.USD","LU0795875169.SGD","LU0210528500.USD","FRTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673016634","title":"Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Stryker (SYK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673016634","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673016634?lang=en_us&edition=fundamental","pubTime":"2026-10-07 22:00","pubTimestamp":1791381626,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Envista Holdings (NVST) and Stryker (SYK) with bulli...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-envista-holdings-nvst-and-stryker-syk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-envista-holdings-nvst-and-stryker-syk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z6F94.USD","BK4588","BK4082","BK4585","LU0882574055.USD","LU1201861165.SGD","SYK","LU2362541273.HKD","LU0289739699.SGD","LU0432979614.USD","LU0130103400.USD","LU0950375773.USD","XBI","LU2506951958.HKD","LU0690374961.EUR","LU2506951875.HKD","IE0034390439.USD","LU1983299246.USD","LU2324357040.USD","BK4504","LU2468319806.SGD","BK4137","LU0058720904.USD","LU0130518102.USD","IHI","LU0114720955.EUR","LU1791710400.SGD","LU2404859741.USD","LU2404859667.USD","LU0648000940.SGD","LU2089984988.USD","LU2506952170.USD","LU2362540622.SGD","NVST","LU0823417737.USD","LABU","BK4566","LU0029874061.USD","LU0528227936.USD","LU0477156797.USD","LU0128526141.USD","BK4581","GB00B4QBRK32.GBP","LU2362541513.USD","XLV","LU1791710582.SGD","HCSG","LU0690374615.EUR","LU0823417653.USD","LU2506952097.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673015601","title":"Ultragenyx Monetizes FDA Priority Review Voucher Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2673015601","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673015601?lang=en_us&edition=fundamental","pubTime":"2026-10-07 21:32","pubTimestamp":1791379976,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical ( ($RARE) ) has issued an update. On October 6, 2026, Ultragenyx Pharmaceutical Inc. entered into an asset purchase agree...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ultragenyx-monetizes-fda-priority-review-voucher-asset?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ultragenyx-monetizes-fda-priority-review-voucher-asset?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673159350","title":"Clearmind Medicine submits psychedelic therapy recommendations to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2673159350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673159350?lang=en_us&edition=fundamental","pubTime":"2026-10-07 21:25","pubTimestamp":1791379525,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced it submitted recommendations to the FDA under Docket FDA-2026-N-7542 on future therapeutic use of psychedelic d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-submits-psychedelic-therapy-recommendations-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-submits-psychedelic-therapy-recommendations-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PSIL","LABU","CMND","BK4585","PSYK","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673130070","title":"Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2673130070","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673130070?lang=en_us&edition=fundamental","pubTime":"2026-10-07 21:22","pubTimestamp":1791379373,"startTime":"0","endTime":"0","summary":"Healthcare stocks were flat to higher pre-bell Wednesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4%.Danaher (DHR) stock wa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DHR","IE00BKVL7J92.USD","SGXZ57979304.SGD","BK4137","FMED","BK4121","IE00BQXX3C00.GBP","SG9999004303.SGD","LU0289960550.SGD","LU1551013425.SGD","XLV","BK4588","LABU","LU1267930730.SGD","LU0114720955.EUR","LU2106854487.HKD","BK4504","XBI","DHR.AU","LU0882574055.USD","LU0320765059.SGD","ARWR","SG9999013999.USD","LU0689472784.USD","LU2125910179.SGD","LU2355687059.USD","LU2112291526.USD","IE00BZ1G4Q59.USD","LU0187121727.USD","LU0289739343.SGD","LU0528227936.USD","SG9999001176.SGD","LU0122379950.USD","BK4533","LU1061106388.HKD","IBB","LU1023059063.AUD","BK4534","NEOG","BK4581","LU1791710582.SGD","IE0004445239.USD","IE00BQXX3F31.USD","LU0312595415.SGD","LU0820562030.AUD","IE000M9KFDE8.USD","LU1804176565.USD","LU2125909247.SGD","HCSG","LU2265009873.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673901382","title":"Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2673901382","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673901382?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:40","pubTimestamp":1791376800,"startTime":"0","endTime":"0","summary":"Company Calls for Consideration of New Regulatory Pathways and Cost Saving of Non-Hallucinogenic Neuroplastogens for Alcohol Use Disorder Vancouver, Canada, Oct.  07, 2026 (GLOBE NEWSWIRE) --  Clearmi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376478/0/en/clearmind-advances-dialogue-with-u-s-federal-government-on-psychedelic-therapies-submitting-recommendations-to-fda.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4009","LABU","HHS","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673018273","title":"AbbVie’s telisotuzumab adizutecan gets two FDA Breakthrough Therapy Designations","url":"https://stock-news.laohu8.com/highlight/detail?id=2673018273","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673018273?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:36","pubTimestamp":1791376566,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) announced that the U.S. FDA has granted two Breakthrough Therapy Designations for telisotuzumab adizutecan in colorectal cancer and n...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbvies-telisotuzumab-adizutecan-gets-two-fda-breakthrough-therapy-designations-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbvies-telisotuzumab-adizutecan-gets-two-fda-breakthrough-therapy-designations-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLAM","SG9999015986.USD","LU1670627923.USD","LU2089284900.SGD","BK4559","LU1551013425.SGD","XLV","LU0708994859.HKD","LABU","LU1989772923.USD","RXL","IE00BGHQF631.EUR","LU2237443549.SGD","IE00BLSP4239.USD","MEDX","PJP","LU1496350171.SGD","LU0689472784.USD","LU0417517546.SGD","FTXH","IE00B19Z3581.USD","LU0029864427.USD","SG9999015978.USD","LU0965508806.USD","FHLC","LU2112291526.USD","IE00BJT1NW94.SGD","AGNG","IE000F7OJYX1.SGD","LU1548497426.USD","JDOC","BK4581","LU1496350502.SGD","LU1989772840.SGD","VHT","LU1839511570.USD","SG9999003800.SGD","IE00BN8TJ469.HKD","PPH","IE0004445239.USD","LU0158827948.USD","TRUH","BK4550","IXJ","IYH","IE00B4R5TH58.HKD","LU0456855351.SGD","LU1093756325.SGD","ABBV","LU0738911758.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673203018","title":"Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673203018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673203018?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:30","pubTimestamp":1791376237,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on BridgeBio Pharma (BBIO) and Vaxcyte (PCVX). BridgeBio Pharma (BBI...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-bridgebio-pharma-bbio-and-vaxcyte-pcvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-bridgebio-pharma-bbio-and-vaxcyte-pcvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","IE0009354923.USD","BK4505","LABU","LU0053671581.USD","BK4588","BK4139","BBIO","BK4585","HCSG","XBI","XLV","PCVX","BK4581","LU0029874061.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673018304","title":"FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition","url":"https://stock-news.laohu8.com/highlight/detail?id=2673018304","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673018304?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:16","pubTimestamp":1791375360,"startTime":"0","endTime":"0","summary":"Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376442/0/en/fda-grants-seastar-medical-breakthrough-device-designation-for-its-scd-therapy-for-the-treatment-of-hyperinflammation-in-adult-patients-with-sepsis-or-a-septic-condition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673185830","title":"VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of  Non-Animal Testing Methods","url":"https://stock-news.laohu8.com/highlight/detail?id=2673185830","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673185830?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:05","pubTimestamp":1791374700,"startTime":"0","endTime":"0","summary":"As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costsSAN DIEGO, Oct.  07, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VI","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376437/37000/en/vivosim-labs-celebrates-updated-fda-regulations-allowing-greater-use-of-non-animal-testing-methods.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673873090","title":"J.P. Morgan Remains a Buy on Gilead Sciences (GILD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673873090","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673873090?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:37","pubTimestamp":1791373071,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences today and set a price target of $170.00. Schott covers the Healthcare s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-gilead-sciences-gild-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-gilead-sciences-gild-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBXU","LU1548497426.USD","GILD","LU0098860793.USD","LU0912757837.SGD","LU0965509010.AUD","LU2133065610.SGD","BK4583","LU1934455277.USD","TMED","LU1571399168.USD","BMED","LU0882574139.USD","BK4568","BK4585","LU0114720955.EUR","LU0859254822.USD","LU2028103732.USD","XBI","LU0882574055.USD","IBBQ","LU1934455194.USD","BIB","BK4578","LU1989772840.SGD","LU1934455863.HKD","SG9999015978.USD","LU0889565916.HKD","LU0234570918.USD","LU1791710582.SGD","XLV","LU1778281490.HKD","LU1064131342.USD","IBB","LU1244550221.USD","BK4588","BK4504","IAI","IE00BZ1G4Q59.USD","LABU","LU0267386448.USD","LU1066051498.USD","LU2324357040.USD","BBH","MEDI","KBWB","LU1674673691.USD","IE00BKVL7J92.USD","IE00B19Z3581.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673903660","title":"Arrowhead announces US FDA granted plozasiran entry into STAR program","url":"https://stock-news.laohu8.com/highlight/detail?id=2673903660","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673903660?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:36","pubTimestamp":1791372976,"startTime":"0","endTime":"0","summary":"Arrowhead (ARWR) Pharmaceuticals announced that the United States Food and Drug Administration, FDA, has granted plozasiran entry in the Split Real...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrowhead-announces-us-fda-granted-plozasiran-entry-into-star-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrowhead-announces-us-fda-granted-plozasiran-entry-into-star-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARWR","BK4139","BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673078092","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2673078092","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673078092?lang=en_us&edition=fundamental","pubTime":"2026-10-07 18:50","pubTimestamp":1791370229,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BridgeBio Pharma (BBIO), Henry Schein (HSIC) and Str...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-374?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-374?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","XLV","HSIC","BK4137","BK4505","BK4585","BK4175","LU0029874061.USD","BBIO","HCSG","XBI","BK4139","LU1815336091.USD","LABU","BK4588","BK4581","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673509465","title":"Analysts’ Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673509465","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673509465?lang=en_us&edition=fundamental","pubTime":"2026-10-07 17:50","pubTimestamp":1791366612,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ArriVent BioPharma, Inc. (AVBP), Definium Therapeuti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-arrivent-biopharma-inc-avbp-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-arrivent-biopharma-inc-avbp-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","AVBP","BK4588","BK4007","BK4139","XLV","LU0029874061.USD","BK4585","HCSG","XBI","BK4137","LABU","BK4581","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673423099","title":"Otsuka Subsidiary Initiates US FDA Submission for Kidney Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2673423099","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673423099?lang=en_us&edition=fundamental","pubTime":"2026-10-07 17:03","pubTimestamp":1791363820,"startTime":"0","endTime":"0","summary":"Otsuka  said its wholly owned unit, Otsuka Pharmaceutical Development & Commercialization, completed a rolling submission application to the US Food and Drug Administration for approval of its sibeprenlimab, Voyxact, on Tuesday.The Japan-based drug maker said that the drug is used to reduce proteinuria in adults with IgA nephropathy at risk for disease progression, according to a Wednesday filing with the Tokyo bourse.The company said that the drug secured accelerated approval last year.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673709943","title":"Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673709943","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673709943?lang=en_us&edition=fundamental","pubTime":"2026-10-07 17:01","pubTimestamp":1791363707,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics  is on track to start its phase 3 trial of relcobatinib in patients with previously treated chronic myeloid leukemia before the end of 2026, the company said Wednesday.The move comes after the company aligned with the US Food and Drug Administration on the trial's final design.The trial is designed to directly compare relcobatinib with second-generation tyrosine kinase inhibitors and is expected to enroll 450 adults with chronic myeloid leukemia.The primary endpoint is major molecular response at week 24, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","BK4139","BK4588","ELVN","LABU","BK4585","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":3,"totalSize":419,"code":"91000000","status":"200"}]}}